We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

133 hedge funds and large institutions have $826M invested in BioCryst Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 25

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

53% more call options, than puts

Call options by funds: $8.87M | Put options by funds: $5.79M

8% more funds holding

Funds holding: 123 → 133 (+10)

1% more capital invested

Capital invested by funds: $817M → $826M (+$8.86M)

0.25% less ownership

Funds ownership: 92.34% → 92.09% (-0.25%)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
133
Holders Change
+10
Holders Change %
+8.13%
% of All Funds
2.88%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
21
Increased
52
Reduced
25
Closed
11
Calls
$8.87M
Puts
$5.79M
Net Calls
+$3.07M
Net Calls Change
+$2.42M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$12.7M
2
Millennium Management
Millennium Management
New York
+$6.41M
3
State Street
State Street
Massachusetts
+$6.11M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.08M
5
UBS Group
UBS Group
Switzerland
+$3.3M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$17.1M
2
GPP
Great Point Partners
Connecticut
-$14.3M
3
EAM
Eventide Asset Management
Massachusetts
-$8.45M
4
Jennison Associates
Jennison Associates
New York
-$5.98M
5
DM
Deerfield Management
New York
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
51
California Public Employees Retirement System
California
$916K -$310K -36,152 -24%
Squarepoint
52
Squarepoint
New York
$914K +$557K +65,055 +138%
Barclays
53
Barclays
United Kingdom
$861K +$556K +64,891 +159%
Rafferty Asset Management
54
Rafferty Asset Management
New York
$855K +$899K +105,040 New
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$829K – – –
Wells Fargo
56
Wells Fargo
California
$696K +$166K +19,386 +29%
ARTA
57
A.R.T. Advisors
New York
$677K +$713K +83,230 New
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$585K +$35.5K +4,151 +6%
AIG
59
American International Group
New York
$566K -$19.3K -2,254 -3%
FSA
60
Franklin Street Advisors
North Carolina
$521K +$171K +20,000 +45%
UBS AM
61
UBS AM
Illinois
$498K +$112K +13,126 +27%
TCS
62
Texas Children's
Texas
$492K +$518K +60,479 New
SEI Investments
63
SEI Investments
Pennsylvania
$483K -$141K -16,472 -22%
State Board of Administration of Florida Retirement System
64
State Board of Administration of Florida Retirement System
Florida
$443K – – –
MIM
65
MetLife Investment Management
New Jersey
$412K – – –
CCMU
66
Cheyne Capital Management (UK)
United Kingdom
$407K – – –
ProShare Advisors
67
ProShare Advisors
Maryland
$400K +$3.86K +451 +0.9%
SIM
68
Spark Investment Management
New York
$392K +$413K +48,200 New
Point72 Asset Management
69
Point72 Asset Management
Connecticut
$386K -$2.59M -302,547 -86%
AQR Capital Management
70
AQR Capital Management
Connecticut
$382K +$18.7K +2,185 +5%
HI
71
HBK Investments
Texas
$377K +$396K +46,268 New
VOYA Investment Management
72
VOYA Investment Management
Georgia
$371K – – –
Commonwealth Equity Services
73
Commonwealth Equity Services
Massachusetts
$352K – – –
GCP
74
GSA Capital Partners
United Kingdom
$329K +$346K +40,383 New
MLICM
75
Metropolitan Life Insurance Company (MetLife)
New York
$301K – – –
1 2
3
4 5

BCRX Hedge Fund Activity: Q1 2019 in Review

133 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2019, worth a combined $826M — up 1.1% from $817M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BCRX positions and 11 closed out — a net gain of 10 holders — while 52 added to existing stakes and 25 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $12.7M. The largest seller was RA Capital Management, cutting an estimated $17.1M.

  • 133 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2019, up from 123 in Q4 2018.
  • Funds reported $826M of BioCryst Pharmaceuticals stock for Q1 2019, up 1.1% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q1 2019 and 11 closed out, a net change of +10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2019 was Citadel Advisors, an estimated $12.7M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2019 was RA Capital Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q1 2019.